Loading clinical trials...
Loading clinical trials...
The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD. Ho...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
NCT06218589 · Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT03151473 · Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
NCT02754037 · Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
NCT07172997 · MASLD, T2DM (Type 2 Diabetes Mellitus), and more
NCT06913699 · Non-alcoholic Fatty Liver Disease (NAFLD)
The First Hospital Affiliated to Xiamen University
Xiamen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions